n6 Tec Completes Growth Financing from Telegraph Hill Partners to Support Launch of Novel iconPCR™ Platform

Pleasanton, California February 7, 2024 – n6 Tec Inc., a next generation sequencing and molecular biology platform company, announced the completion of a growth investment from Telegraph Hill Partners (THP), a venture capital firm focused on partnering with innovative life science companies. This partnership will allow n6 to further develop and commercialize its novel iconPCR™ technology for improved genomics workflows.  

iconPCR is the next generation of thermocycling technology which enables 96 independently controlled PCR reactions simultaneously. This transformative platform brings together advances from orthogonal industries including semiconductor and telecom to provide the highest quality next generation sequencing (NGS) data by dramatically improving workflows across virtually all NGS assays.

“We are thrilled to have THP as a partner and investor in our company,” said Pranav Patel, founder and CEO of n6 Tec. “The financing will help us launch and commercialize our pioneering platform and will also provide resources for our continued product development and company growth. “

n6 Tec will leverage THP’s extensive industry experience, network, and strategic guidance, further enhancing the company’s ability to meet the evolving needs of the genomics industry. 

“n6’s groundbreaking platform for sample preparation can enable improved efficiencies and superior results for life science and diagnostic labs,” said Deval Lashkari, Senior Partner at THP. “We are very excited to partner with the n6 team as they accelerate efforts to commercialize iconPCR and drive advancements in genomics.” 

Deval Lashkari from THP will join the n6 Tec board concurrent with the financing.


About n6 Tec:

n6 Tec is a pioneering iconPCR platform that will transform the field of molecular biology and next generation sequencing sample preparation. More information can be found at www.n6tec.com.


About Telegraph Hill Partners:

Telegraph Hill Partners, founded in 2001 and based in San Francisco, CA, invests in life science, medical technology, and healthcare companies. For more information, please see  www.telegraphhillpartners.com.